<DOC>
	<DOCNO>NCT02805725</DOCNO>
	<brief_summary>Assessment efficacy safety trabectedin metronomic cyclophosphamide ( CP ) patient advance pretreated soft-tissue sarcoma , Maximum Tolerated Dose ( MTD ) determine ( phase I trial ) .</brief_summary>
	<brief_title>Targeting Microenvironment Cellular Immunity Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide</brief_title>
	<detailed_description>Phase I : Multicenter Phase I trial base dose escalation study design ( 3+3 traditional design ) . Phase II : One-arm , multicenter Phase II trial base two-stage optimal Simon 's design .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>1 . Patients softtissue sarcoma histologically confirm central review 2 . Metastatic unresectable locally advanced disease , 3 . Age ≥ 18 year , 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 2 , 5 . Life expectancy &gt; 3 month , 6 . Measurable disease accord RECIST v1.1 outside previously irradiated field , 7 . For patient include phase II study , progressive disease accord RECIST v1.1 criterion diagnose basis two CT scan MRI obtain interval less 6 month period 12 month prior inclusion confirm central review , 8 . Previous use Anthracyclines , 9 . Have provide tissue archival tissue sample , 10 . At least three week since last chemotherapy , immunotherapy pharmacological treatment and/or radiotherapy , 11 . Adequate hematological , renal , metabolic hepatic function : 1 . Hemoglobin ≥ 9 g/dl ( patient may receive prior red blood cell [ RBC ] transfusion , clinically indicate ) ; absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/l , platelet count ≥ 100 x 10^9/l 2 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &lt; = 2.5 x upper limit normality ( ULN ) ( &lt; = 5 case extensive liver involvement ) alkaline phosphatase ( AP ) &lt; = 2.5 x ULN 3 . Total bilirubin &lt; = ULN . 4 . Albumin ≥ 25 g/l 5 . Serum Creatinine &lt; =1.5 x ULN calculate creatinine clearance ( CrCl ) ≥ 30 ml/min ( accord Cockroft formula ) . 6 . Creatine Phosphokinase ( CPK ) &lt; = 2.5 x ULN 12 . Women childbearing potential must negative serum pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period six month discontinuation treatment . Acceptable method contraception include intrauterine device ( IUD ) , oral contraceptive , subdermal implant double barrier , 13 . No prior concurrent malignant disease diagnose treat last 2 year except adequately treat situ carcinoma cervix , basal squamous skin cell carcinoma , situ transitional bladder cell carcinoma , 14 . Recovery grade ≤ 1 adverse event ( AE ) derive previous treatment ( exclude alopecia grade nonpainful peripheral neuropathy grade ≤ 2 ) accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE , version 4.0 ) , 15 . Patients French social security compliance Law relate biomedical research ( Article 112111 French Public Health Code ) , 16 . Voluntarily sign date write informed consent prior study specific procedure . 1 . Previous treatment Trabectedin , 2 . Currently active bacterial fungus infection ( &gt; grade 2 CTC [ CTCAE ] HIV1 , HIV2 , hepatitis B hepatitis C infection , 3 . History chronic alcohol use and/or cirrhosis , 4 . The follow unstable cardiac condition allow : Congestive heart failure Angina pectoris Myocardial infarction within 1 year registration Uncontrolled arterial hypertension define blood pressure ≥ 150/100 mmHg despite optimal medical therapy Arrhythmias clinically significant 5 . Patients unable receive corticotherapy , 6 . Known central nervous system malignancy ( CNS ) , 7 . Men woman childbearing potential use effective method contraception previously describe ; woman pregnant breast feeding , 8 . Participation study involve medical therapeutic intervention last 30 day , 9 . Previous enrolment present study , 10 . Patient unable follow comply study procedure geographical , social psychological reason , 11 . Known hypersensitivity involve study drug formulation component . 12 . Recent vaccination ( last 2 week inclusion ) yellow fever .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Advanced pretreated soft tissue sarcoma</keyword>
	<keyword>Phase I/II trial</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>PK study</keyword>
</DOC>